Cargando…

Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin

BACKGROUND: The therapeutic management of carbapenem-resistant Acinetobacter baumannii (CR-AB) represents a serious challenge to the public health sector because these pathogens are resistant to a wide range of antibiotics, resulting in limited treatment options. The present study was planned to inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejaz, Hasan, Ahmad, Mahtab, Younas, Sonia, Junaid, Kashaf, Abosalif, Khalid Omer Abdalla, Abdalla, Abualgasim Elgaili, Alameen, Ayman Ali Mohammed, Elamir, Mohammed Yagoub Mohammed, Bukhari, Syed Nasir Abbas, Ahmad, Naveed, Qamar, Muhammad Usman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164867/
https://www.ncbi.nlm.nih.gov/pubmed/34079303
http://dx.doi.org/10.2147/IDR.S310478
_version_ 1783701207541350400
author Ejaz, Hasan
Ahmad, Mahtab
Younas, Sonia
Junaid, Kashaf
Abosalif, Khalid Omer Abdalla
Abdalla, Abualgasim Elgaili
Alameen, Ayman Ali Mohammed
Elamir, Mohammed Yagoub Mohammed
Bukhari, Syed Nasir Abbas
Ahmad, Naveed
Qamar, Muhammad Usman
author_facet Ejaz, Hasan
Ahmad, Mahtab
Younas, Sonia
Junaid, Kashaf
Abosalif, Khalid Omer Abdalla
Abdalla, Abualgasim Elgaili
Alameen, Ayman Ali Mohammed
Elamir, Mohammed Yagoub Mohammed
Bukhari, Syed Nasir Abbas
Ahmad, Naveed
Qamar, Muhammad Usman
author_sort Ejaz, Hasan
collection PubMed
description BACKGROUND: The therapeutic management of carbapenem-resistant Acinetobacter baumannii (CR-AB) represents a serious challenge to the public health sector because these pathogens are resistant to a wide range of antibiotics, resulting in limited treatment options. The present study was planned to investigate the clonal spread of CR-AB in a clinical setting. METHODOLOGY: A total of 174 A. baumannii clinical isolates were collected from a tertiary care hospitals in Lahore, Pakistan. The isolates were confirmed by VITEK 2 compact system and molecular identification of recA and bla(OXA-51). Antimicrobial profile and the screening of carbapenem-resistant genes were carried out using VITEK 2 system and PCR, respectively. The molecular typing of the isolates was performed according to the Pasteur scheme. RESULTS: Of the 174 A. baumannii isolates collected, the majority were isolated from sputum samples (46.5%) and in the intensive care unit (ICU, 75%). Among these, 113/174 (64.9%) were identified as CR-AB, and 49.5% and 24.7% harbored bla(OXA-23) and bla(NDM-1), respectively. A total of 11 (9.7%) isolates co-harbored bla(OXA-51), bla(NDM-1), and bla(OXA-23). Interestingly, 46.9% of the CR-AB belonged to sequence type 2 (ST2; CC1), whereas 15.9% belonged to ST1 (CC1). All of the CR-AB isolates showed extensive resistance to clinically relevant antibiotics, except colistin. CONCLUSION: The study concluded CR-AB ST2 clone harboring bla(OXA-23) and bla(NDM-1) are widely distributed in Pakistan’s clinical settings, which could result in increased mortality. Strict compliance with the National Action Plan on Antimicrobial Resistance is necessary to reduce the impacts of these strains.
format Online
Article
Text
id pubmed-8164867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81648672021-06-01 Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin Ejaz, Hasan Ahmad, Mahtab Younas, Sonia Junaid, Kashaf Abosalif, Khalid Omer Abdalla Abdalla, Abualgasim Elgaili Alameen, Ayman Ali Mohammed Elamir, Mohammed Yagoub Mohammed Bukhari, Syed Nasir Abbas Ahmad, Naveed Qamar, Muhammad Usman Infect Drug Resist Original Research BACKGROUND: The therapeutic management of carbapenem-resistant Acinetobacter baumannii (CR-AB) represents a serious challenge to the public health sector because these pathogens are resistant to a wide range of antibiotics, resulting in limited treatment options. The present study was planned to investigate the clonal spread of CR-AB in a clinical setting. METHODOLOGY: A total of 174 A. baumannii clinical isolates were collected from a tertiary care hospitals in Lahore, Pakistan. The isolates were confirmed by VITEK 2 compact system and molecular identification of recA and bla(OXA-51). Antimicrobial profile and the screening of carbapenem-resistant genes were carried out using VITEK 2 system and PCR, respectively. The molecular typing of the isolates was performed according to the Pasteur scheme. RESULTS: Of the 174 A. baumannii isolates collected, the majority were isolated from sputum samples (46.5%) and in the intensive care unit (ICU, 75%). Among these, 113/174 (64.9%) were identified as CR-AB, and 49.5% and 24.7% harbored bla(OXA-23) and bla(NDM-1), respectively. A total of 11 (9.7%) isolates co-harbored bla(OXA-51), bla(NDM-1), and bla(OXA-23). Interestingly, 46.9% of the CR-AB belonged to sequence type 2 (ST2; CC1), whereas 15.9% belonged to ST1 (CC1). All of the CR-AB isolates showed extensive resistance to clinically relevant antibiotics, except colistin. CONCLUSION: The study concluded CR-AB ST2 clone harboring bla(OXA-23) and bla(NDM-1) are widely distributed in Pakistan’s clinical settings, which could result in increased mortality. Strict compliance with the National Action Plan on Antimicrobial Resistance is necessary to reduce the impacts of these strains. Dove 2021-05-25 /pmc/articles/PMC8164867/ /pubmed/34079303 http://dx.doi.org/10.2147/IDR.S310478 Text en © 2021 Ejaz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ejaz, Hasan
Ahmad, Mahtab
Younas, Sonia
Junaid, Kashaf
Abosalif, Khalid Omer Abdalla
Abdalla, Abualgasim Elgaili
Alameen, Ayman Ali Mohammed
Elamir, Mohammed Yagoub Mohammed
Bukhari, Syed Nasir Abbas
Ahmad, Naveed
Qamar, Muhammad Usman
Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title_full Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title_fullStr Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title_full_unstemmed Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title_short Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla(NDM) and bla(OXA) From Clinical Origin
title_sort molecular epidemiology of extensively-drug resistant acinetobacter baumannii sequence type 2 co-harboring bla(ndm) and bla(oxa) from clinical origin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164867/
https://www.ncbi.nlm.nih.gov/pubmed/34079303
http://dx.doi.org/10.2147/IDR.S310478
work_keys_str_mv AT ejazhasan molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT ahmadmahtab molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT younassonia molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT junaidkashaf molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT abosalifkhalidomerabdalla molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT abdallaabualgasimelgaili molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT alameenaymanalimohammed molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT elamirmohammedyagoubmohammed molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT bukharisyednasirabbas molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT ahmadnaveed molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin
AT qamarmuhammadusman molecularepidemiologyofextensivelydrugresistantacinetobacterbaumanniisequencetype2coharboringblandmandblaoxafromclinicalorigin